Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; Department of Dental Anesthesiology, Osaka University Graduate School of Dentistry, Osaka, Japan.
J Clin Lipidol. 2019 Mar-Apr;13(2):317-325. doi: 10.1016/j.jacl.2019.01.002. Epub 2019 Jan 11.
We previously reported that the patients with cholesteryl ester transfer protein (CETP) deficiency (CETP-D) show marked changes in the size and lipid compositions of high-density lipoprotein (HDL) and that they are not protected from atherosclerotic cardiovascular diseases, despite increased serum HDL-cholesterol (HDL-C) levels. HDL particles carry a variety of proteins, some of which are known to have antiatherogenic functions.
This study aimed to investigate the protein composition of HDL particles in patients with CETP-D.
Eight patients with complete deficiency of CETP and 8 normolipidemic healthy subjects were enrolled. We performed shotgun proteomic analysis to investigate the proteome of ultracentrifugally isolated HDL.
We identified 79 HDL-associated proteins involved in lipid metabolism, protease inhibition, complement regulation, and acute-phase response, including 5 potential newly identified HDL-associated proteins such as angiopoietin-like3 (ANGPTL3). Spectral counts of apolipoprotein (apo) E were increased in patients with CETP-D compared with controls (60.3 ± 6.9 vs 43.7 ± 2.5, P < .001), which is concordant with our previous report. Complement regulatory proteins such as C3, C4a, C4b, and C9 were also significantly enriched in HDL from patients with CETP-D. Furthermore, apoC-III and ANGPTL3, both of which are now known to associate with increased atherosclerotic cardiovascular diseases, were enriched in patients with CETP-D compared with normolipidemic subjects (35.9 ± 5.3 vs 27.1 ± 3.7, 2.3 ± 1.1 vs 0.4 ± 1.1, respectively; P < .01).
We have characterized HDL-associated proteins in patients with CETP-D. We identified a significant increase in the amount of apoE, apoC-III, ANGPTL3, and complement regulatory proteins. These proteomic changes might be partly responsible for the enhanced atherogenicity of patients with CETP-D.
我们之前曾报道过,胆固醇酯转移蛋白(CETP)缺乏症(CETP-D)患者的高密度脂蛋白(HDL)大小和脂质组成发生明显变化,尽管血清 HDL-胆固醇(HDL-C)水平升高,但他们仍不能预防动脉粥样硬化性心血管疾病。HDL 颗粒携带多种蛋白质,其中一些已知具有抗动脉粥样硬化作用。
本研究旨在研究 CETP-D 患者 HDL 颗粒的蛋白质组成。
纳入 8 例完全缺乏 CETP 的患者和 8 例血脂正常的健康对照者。我们进行了鸟枪法蛋白质组学分析,以研究超速离心分离的 HDL 的蛋白质组。
我们鉴定出 79 种与脂质代谢、蛋白酶抑制、补体调节和急性期反应相关的 HDL 相关蛋白,包括 5 种潜在的新发现的 HDL 相关蛋白,如血管生成素样蛋白 3(ANGPTL3)。与对照组相比,CETP-D 患者的载脂蛋白(apo)E 谱计数增加(60.3±6.9 对 43.7±2.5,P<.001),这与我们之前的报告一致。补体调节蛋白如 C3、C4a、C4b 和 C9 也在 CETP-D 患者的 HDL 中明显富集。此外,apoC-III 和 ANGPTL3 与动脉粥样硬化性心血管疾病的风险增加有关,与血脂正常的受试者相比,这两种蛋白在 CETP-D 患者中也明显富集(35.9±5.3 对 27.1±3.7,2.3±1.1 对 0.4±1.1,P<.01)。
我们对 CETP-D 患者的 HDL 相关蛋白进行了特征描述。我们发现 apoE、apoC-III、ANGPTL3 和补体调节蛋白的含量显著增加。这些蛋白质组学变化可能部分解释了 CETP-D 患者的促动脉粥样硬化作用增强的原因。